Pulmonary Sarcoidosis
Conditions
Brief summary
The goal of the current study is to evaluate the potential of the selected PET tracers to detect sarcoidotic lesions in lungs. The tracers are already in clinical use for the detection of certain inflammatory processes or malignant tumors, and their targets present similarities with molecular mechanisms of sarcoidosis.
Detailed description
The diagnosis of sarcoidosis is difficult since there is no specific noninvasive method available to diagnose sarcoidosis. FDG-PET imaging is in use, however, FDG is not a specific tracer for sarcoidosis and other inflammatory diseases may interfere with the imaging findings. The aim of the current protocol is to evaluate the potential of other inflammatory PET-tracers in the detection of sarcoidotic lesions. The patients with active sarcoidotic lesions in lungs will be recruited. First, the patient undergoes PET-FDG scan and then the patient undergoes the PET scan either with C11-methionine or 68Ga-DOTANOC. The results with the latter tracers will be compared to the imaging results with FDG.
Interventions
DRUGMethionine
Subject undergoes imaging studies with FDG and with methionine.
DRUGDOTANOC
Subject undergoes imaging studies with FDG and with DOTANOC.
Sponsors
Turku University Hospital
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patient with sarcoidosis
Exclusion criteria
* any malignant disease * any significant other inflammatory or infectious disease affecting lungs * pregnancy
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The detection of sarcoidotic lesion with C11-methionine or 68Ga-DOTANOC. | baseline | Qualitative assessment of tracer uptake in sarcoidotic lesions. |
Countries
Finland
Contacts
Primary ContactRiikka Lautamaki, MD, PhD
Outcome results
None listed